Paradigm Spine, LLC has announced that leading spine surgeon Hallett Mathews, M.D., M.B.A. has joined the company as its Executive Vice President and Chief Medical Officer. Dr. Mathews now has global responsibility for all medical education initiatives, surgeon/faculty training functionalities. He is in charge of the strategic management of the company’s clinical, compliance and regulatory policies, as they relate to its worldwide product portfolio of spine medical devices.
Hallett Mathews, M.D. Joins Paradigm Spine

Dr. Mathews is a board certified orthopedic spinal surgeon who practiced spinal surgery for 22 years. He was recruited from clinical practice by Medtronic Spine and Biologics in 2005 to become their Vice President of Medical Affairs, and later served within the capacity of Vice President of Clinical Affairs, ultimately becoming Chief Medical Officer. Prior to joining Medtronic, Dr. Mathews was President of MidAtlantic Spine Specialists in Richmond and Williamsburg, Virginia, where he owned and practiced in a private multi-disciplinary spine surgery practice. Also, prior to joining Medtronic, Dr. Mathews was an Associate Clinical Professor of Orthopedic and Neurologic Surgery at Virginia Commonwealth University in Richmond, Virginia.
Prior to joining Paradigm Spine, Dr. Mathews was the President of Musculoskeletal, Clinical and Regulatory Advisors, LLC. Dr. Mathews is a former member of the Board of Directors of the North American Spine Society; former member of the Board of Directors of the Spine Arthroplasty Society; and member and past President for the International Society for Minimally Invasive Spine Surgery. Dr. Mathews earned his medical degree at the Virginia Commonwealth University, Medical College of Virginia, and completed his M.B.A. at the University of Tennessee in Knoxville.
Dr. Mathews told OTW,
Paradigm is at the precipice of great opportunity in the spinal medical device space. One of my first roles as EVP and CMO will be to establish world class, pertinent, quality and compliant medical education and training for all of Paradigm Spine products both now and in the future. I will also be helping the company redefine process and procedural innovation that affects all companies in this space using comparative effectiveness level one data that includes both long term patient outcomes and prospectively collected economic data to improve choice, quality, and outcomes for all stakeholders. I believe Paradigm Spine will become a significant force of change in a market that has been dominated by high sales and distribution costs, little true innovation, and little evidence to support this 25 year era of spine care.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.